Stock Market Reviews

ENLV (Enlivex Therapeutics Ltd.) News

Get the latest news, insights, and market updates on ENLV (Enlivex Therapeutics Ltd.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enlivex Therapeutics announces new listing of RAIN token on Kraken
  Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.President's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFl
  Feb 11, 2026 - $ENLV
• RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance
  ORLANDO, FL / ACCESS Newswire / February 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Fintech & Digital Asset Treasury ...
  Feb 9, 2026 - $ENLV
• RedChip Spotlights the Future of Finance at Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference on February 4
  ORLANDO, FLORIDA / ACCESS Newswire / January 27, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming Fintech & DATS (Digital Asset Treasury Strategy) ...
  Jan 27, 2026 - $ENLV
• Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
  Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initi
  Jan 23, 2026 - $ENLV
• Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market
  Biopharma firm sets its sights on Rain Protocol’s native token. Rain is an Arbitrum-based prediction market protocol. Prediction markets tipped to reach $96 billion in 10 years.
  Nov 25, 2025 - $ENLV
• Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%
  Nasdaq-listed Enlivex Therapeutics has unveiled plans to raise about $212 million in a private placement to build a Rain token-focused digital asset treasury, positioning the project as the first prediction-markets-oriented DAT strategy by a US-listed company. The announcement coincides with a sharp move in the RAIN price on the market, ...
  Nov 24, 2025 - $ENLV
• Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy
  Enlivex Therapeutics is raising $212 million to invest in RAIN, the token of a blockchain-based prediction market, which will become its main treasury reserve asset.
  Nov 24, 2025 - $ENLV
• EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play
  Enlivex Therapeutics Ltd. (NASDAQ:ENLV) on Monday announced a private investment in public equity of 212 million shares at $1.00 per share, representing a premium of 11.5% from the closing price of the stock on November 21, 2025. The company expects gross proceeds of approximately $212 million (funded in a combination of $USD and USDT). Enlivex will use the proceeds from the PIPE to implement the first RAIN prediction markets token treasury strategy, while continuing its focus on the company's c
  Nov 24, 2025 - $ENLV
• Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
  Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis (OA). The six-month follow-up has now been completed for all patients. The results re-affirm the three-month data rep
  Nov 24, 2025 - $ENLV
• BC-Most Active Stocks
  Nu Holdings Ltd. 36,009,954 16.06
  Nov 24, 2025 - $ENLV